Image-guided radiation therapy developer ViewRay has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market MRIdian Linac, the company's linear accelerator-based MRI-guided radiation therapy system.
The first two MRIdian Linac systems in the U.S. are expected to be installed at Henry Ford Hospital in Detroit and Barnes-Jewish Hospital at Washington University in St. Louis.
ViewRay also announced financial highlights for the fourth quarter and full year of 2016 (end-December 31). The company received four new orders for its MRIdian systems in the fourth quarter, totaling $24.3 million, and 13 new orders in 2016, totaling $77 million.
Revenue was $16.1 million in the fourth quarter and $22.2 million for the full year, while net loss was $11 million in the fourth quarter and $50.6 million for fiscal 2016.
